Shares of Dr Reddy's (DRREDDY) jumped 2% on the NSE after the company disclosed a partnership with Takeda to market and distribute its Qdenga dengue vaccine in India’s private market.
Under the agreement, Takeda keeps commercialisation rights in the public sector while Dr Reddy's will handle marketing and distribution in the private sector, a split that lets both firms play to their strengths.
Qdenga, the first dengue vaccine cleared by India's drug regulator for use in children and adults, protects against all four dengue serotypes. It is dosed in two 0.5‑ml shots, three months apart, and does not require pre‑vaccination screening—streamlining roll‑out.
The partnership arrives amid a record 14.4 million global dengue cases in 2024, with 232,425 cases reported in India, underscoring the urgency for wider vaccine access.
Dr Reddy's CEO said the company expects Qdenga to become available in the private market during the first half of 2027, opening a new revenue stream and expanding its vaccine portfolio.
Investors will watch the 2027 launch window closely; early sales figures could lift the company’s earnings profile in the long run. The partnership does not alter Dr Reddy's current quarterly guidance but adds a positive tail for its vaccine business.